Journal
JOURNAL OF LARYNGOLOGY AND OTOLOGY
Volume 134, Issue 2, Pages 159-164Publisher
CAMBRIDGE UNIV PRESS
DOI: 10.1017/S0022215120000316
Keywords
Turmeric; Mucositis; Head And Neck Squamous Cell Carcinoma; Radiation; Chemoradiotherapy
Categories
Ask authors/readers for more resources
Objective To determine the role of turmeric extract in reducing mucositis in patients undergoing radiotherapy for head and neck cancer. Methods Sixty-one patients who underwent radiotherapy were included in the study and randomised into groups A and B. Patients in group A received 500 mg of turmeric extract (BCM-95) thrice daily, while patients in group B received placebo until radiotherapy completion. All patients were assessed for oral mucositis on a weekly basis during treatment and two months post-treatment using the National Cancer Institute Common Terminology Criteria for Adverse Events and World Health Organization criteria. Results Both groups had a similar grade of mucositis in first two weeks of treatment. The severity of mucositis was progressive in the control group, with four patients developing grade 3 mucositis by week four. In group A, however, the majority of patients (73.3 per cent) had grade 1 mucositis after four weeks of treatment. The difference was statistically significant from the third week onwards (p < 0.001). Conclusion Turmeric extract reduces the incidence and severity of radiation-induced mucositis, which can benefit patients undergoing radiation for head and neck cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available